|
|
 |
|
Viewing report
|
|
|
|
End-user Trends in the U.S. Next-Generation Sequencing Market
Frost & Sullivan, Sep 2011, Pages: 93
In 2010, Frost & Sullivan launched an end-user survey to examine the use of genomics technologies, including next-generation sequencing, by researchers in academic and government laboratories, at pharmaceutical and biotechnology companies, and in hospital and clinical laboratories. This analysis is based on results from researchers from the various end-user groups and investigates topics—such as current and future adoption of sequencing technologies; brands, applications, sample types and formats preferred; species researched, and laboratory budgets. The survey screened for respondents with decision-making roles from laboratories within the United States and segmented them by their awareness and adoption of next-generations sequencing.
This study investigates NGS awareness and usage differences between researchers. The graph on the left displays the awareness/adoption segmentation that applies throughout this study, and the graph on the right shows laboratory types by this segmentation. Current users of NGS are more likely than average to be employed at core facilities and less likely to be involved in applied research.
Genome centers and core facilities are most likely to have adopted NGS. Drug discovery and target validation laboratories are least likely to be aware of NGS. Nearly half of basic and applied researchers remain unaware of NGS.
Major findings of this analysis:
- Human samples are the most commonly used species in the sequencing applications analyzed within this study.
- Cultured cells and whole blood are the primary samples types used for these sequencing applications.
- 96-well plates are the most common format used for sequencing, followed by single tubes.
- cDNA sequencing is the most widely used of the sequencing applications analyzed.
- The largest proportion of users plan to initiate ChIP sequencing in the future.
- Roughly four out of ten of sequencing applications analyzed are most commonly conducted internally
at researchers’ own core facilities.
- NGS currently is the least used of the technologies analyzed, but it has the highest rate of adoption intention among researchers who are aware of this technology. Adoption could double over the next two to three
years.
- Current users of NGS favor Illumina as a supplier of next-generation sequencing technologies, with Roche Life Sciences a distant second. Life Technologies, usually considered the second-most preferred provider of NGS behind Illumina in terms of market share, falls to third in this analysis
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
